Novo and Hims to sell obesity drugs together as feud ends, Shares +40% AH

Source: [https://www.reuters.com/business/healthcare-pharmaceuticals/novo-hims-resolve-dispute-will-sell-obesity-drugs-together-bloomberg-news-2026-03-07/](https://www.reuters.com/business/healthcare-pharmaceuticals/novo-hims-resolve-dispute-will-sell-obesity-drugs-together-bloomberg-news-2026-03-07/) Wegovy maker Novo Nordisk (NOVOb.CO), opens new tab plans to sell its ​weight-loss drugs on Hims & Hers Health (HIMS.N), opens new tab ‌platform, bringing an end to a dispute between the two companies that escalated into a legal battle ​last month, Bloomberg News reported on Friday. Hims ​shares surged 39% in after-hours trading after ⁠the report. The report comes nearly a month ​after Novo sued Hims over patent infringement following ​the U.S. telehealth firm's launch, and then cancellation, of a $49 copy of Novo's obesity pill. The U.S. Food and ​Drug Administration had also threatened action against Hims. Novo ​and Hims plan to announce a new partnership as soon ‌as ⁠Monday, the report said, citing a person familiar with the matter. Last year, Novo ended a short-lived agreement to sell its Wegovy weight-loss drug ​through Hims ​over the ⁠company's marketing tactics and continued sales of Wegovy copies. A Novo spokesperson said ​in an e-mailed statement the company ​is "always ⁠in conversation with companies that can help improve patient access to FDA-approved medicines".